Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Rhea-AI Summary

Daxor (DXR) announces expansion of its blood volume analysis (BVA) technology to three regional healthcare facilities across the U.S. through its Tennessee-based ezBVA Lab service. The expansion includes:

• A Midwest academic medical center for outpatient cardiovascular care
• A Wisconsin primary health center for outpatient syncope assessment
• A Southern New Jersey cardiovascular care program for both inpatient and outpatient settings

The CLIA-certified ezBVA Lab delivers comprehensive BVA results within 24 hours, featuring 98% diagnostic accuracy for tailored fluid management. This expansion demonstrates the growing adoption of Daxor's technology in diverse healthcare settings, aimed at improving patient outcomes while reducing costs.

Positive

• Expansion into three new healthcare facilities across different regions
• Technology demonstrates versatility across both inpatient and outpatient settings
• High diagnostic accuracy rate of 98%
• 24-hour results turnaround time through CLIA-certified facility

Negative

• None.

Insights

Healthcare Technology Analyst

Daxor's expansion into three diverse healthcare facilities represents a positive commercial development with strategic implications. The company is successfully penetrating different healthcare segments with their ezBVA Lab service, establishing a presence in academic medical centers, primary care, and specialized cardiovascular programs simultaneously.

The regional diversification across the Midwest, Wisconsin, and New Jersey creates geographic leverage that reduces market concentration risk. Particularly noteworthy is the penetration into an academic medical center, which typically drives clinical validation and can accelerate broader adoption through research publications and physician education.

Daxor's business model leverages their CLIA-certified central laboratory in Tennessee, creating a recurring revenue stream from these facilities. This lab service approach requires less capital investment from healthcare providers while delivering consistent revenue to Daxor, compared to equipment-only sales models.

The 24-hour turnaround capability addresses a critical healthcare need for timely diagnostics, while the application across both inpatient and outpatient settings maximizes the potential utilization scenarios. Without specific contract values disclosed, these implementations should be viewed as validation of market demand rather than immediate financial catalysts, though the cumulative effect of multiple facility adoptions strengthens Daxor's market position and growth trajectory.

Medical Device Industry Expert

Daxor's blood volume analysis technology addresses a fundamental clinical challenge with its 98% diagnostic accuracy for fluid management - a critical factor in treating various cardiovascular conditions. The adoption across three distinct clinical environments demonstrates the versatility of this technology beyond single-use case scenarios.

The implementation specifically for syncope assessment in Wisconsin is particularly notable, as accurate diagnosis of this common condition remains challenging with conventional tools. Blood volume analysis provides objective quantification that can differentiate between cardiac, neurological, and volume-related causes of syncope, potentially reducing unnecessary testing and hospitalizations.

The technology's integration into both outpatient cardiovascular care and comprehensive inpatient/outpatient programs in New Jersey shows clinical validation across the care continuum. This versatility increases the potential utilization rate and return on investment for adopting institutions.

The ezBVA Lab approach eliminates the need for on-site specialized equipment and training, reducing implementation barriers while maintaining centralized quality control. This model allows smaller facilities to access advanced diagnostics previously to major medical centers. For Daxor, this service-based model creates stickier customer relationships compared to one-time equipment sales and aligns with healthcare's shift toward precise, personalized treatments that improve outcomes while controlling costs.

Regional Medical Leaders Embrace Daxor’s ezBVA Lab Service

Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into three regional healthcare facilities across the U.S. These facilities will use Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility equipped with state-of-the-art technology. The ezBVA Lab delivers comprehensive blood volume analysis (BVA) results within 24 hours for both inpatient and outpatient settings, improving patient outcomes while reducing costs.

Recent sales wins include:

• A prominent Midwest academic medical center has integrated Daxor’s BVA technology to enhance outpatient cardiovascular care, marking a significant advancement in regional heart health management
• A Wisconsin primary health center has deployed Daxor’s BVA solution to improve outpatient syncope assessment and treatment, demonstrating the technology's versatility in clinical settings
• A premier cardiovascular care program in Southern New Jersey has adopted Daxor’s BVA technology across inpatient and outpatient settings, underscoring the solution's broad clinical utility and growing reputation in specialized cardiac care

“The expansion of our BVA technology continues with the addition of these diverse healthcare leaders," said Michael Feldschuh, Daxor's CEO and President. From pioneering Midwest academic medical centers and a leading New Jersey cardiovascular institute, our technology is increasingly becoming integral to advanced clinical practice, demonstrating its versatility and growing significance in modern healthcare. Our 98% accurate diagnostic enables physicians to deliver tailored fluid management that improves patient outcomes while reducing costs. Through our ezBVA Lab service, we are expanding our capabilities and furthering our mission to advance healthcare by enabling optimal fluid management with BVA."

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking projections are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What healthcare facilities are adopting Daxor's (DXR) blood volume analysis technology in 2025?

A Midwest academic medical center, a Wisconsin primary health center, and a Southern New Jersey cardiovascular care program are implementing Daxor's BVA technology.

How accurate is Daxor's (DXR) blood volume analysis diagnostic technology?

Daxor's BVA diagnostic technology provides 98% accuracy in blood volume measurements.

What is the turnaround time for Daxor's (DXR) ezBVA Lab results?

The ezBVA Lab delivers comprehensive blood volume analysis results within 24 hours for both inpatient and outpatient settings.

What medical conditions is Daxor's (DXR) BVA technology being used for in these new facilities?

The technology is being used for outpatient cardiovascular care, syncope assessment and treatment, and specialized cardiac care across inpatient and outpatient settings.